Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype.

Blood·2026

Same author

Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states.

Nature genetics·2026

Same author

Hybrid Systems Modeling of Donor T-Cell Responses and Graft-Versus-Host-Disease After Posttransplantation Cyclophosphamide Administration.

CPT: pharmacometrics & systems pharmacology·2026

Same author

Robust predictors for drug response of patients with acute myeloid leukemia.

PloS one·2026

Same author

KGBN: Augmenting and optimizing logical gene regulatory networks using knowledge graphs.

bioRxiv : the preprint server for biology·2026

Same author

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

HemaSphere·2026

Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 28, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia.

Guangrong Qin¹, Jin Dai^2,3, Sylvia Chien^2,3

¹Institute for Systems Biology, Seattle, Washington.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|April 15, 2024

Summary

This summary is machine-generated.

Genetic mutations in acute myeloid leukemia (AML) predict drug response. Identifying these genomic signatures enables personalized treatment strategies for AML patients.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Experiment Videos

Last Updated: Jun 28, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Area of Science:

Genomics
Cancer Biology
Pharmacogenomics

Background:

Acute myeloid leukemia (AML) is characterized by significant genetic heterogeneity, complicating treatment development.
Developing targeted therapies requires understanding the genomic underpinnings of drug sensitivity and resistance.

Purpose of the Study:

To identify genomic signatures for predicting drug response in AML.
To elucidate the genetic basis of drug resistance and sensitivity.
To provide valuable genomic resources for the AML research community.

Main Methods:

Targeted sequencing and high-throughput drug screening of patient-derived leukemia cells.
Single-cell genomic profiling to analyze intra-patient heterogeneity.
Machine learning and statistical analyses to identify predictive mutation patterns.
Integration of large public genomic datasets.

Main Results:

Identified specific genetic signatures correlating with sensitivity or resistance to various therapeutic agents.
Discovered five distinct co-occurring mutation groups within AML.
Single-cell analysis revealed the presence of subclones with co-occurring variants.
Mutation patterns accurately predicted sensitivity to certain drug classes, like MEK inhibitors for RAS-mutated AML.

Conclusions:

Gene mutation patterns are crucial for predicting drug response in AML.
This study provides a framework for classifying AML patients based on mutations to guide drug sensitivity predictions.
The findings support the development of precision medicine approaches for AML treatment.